美第奇新星生物技术 MNOV 深 沪
已收盘 08-01 16:00:00 美东时间
1.43
+0.105
+7.92%
华盛通- 最 高1.50
- 今 开1.50
- 成交量 6.85万股
- 最 低 1.33
- 昨 收 1.325
- 总市值 7013.61万
- 52周最高 2.55
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 1.12
- 委 比 64.47%
- 总股本 4904.62万
- 历史最高 14.50
- 量 比 0.70
- 振 幅 12.83%
- 历史最低 1.12
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
MediciNova, Inc. has entered into a $30 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global LP. Under the agreement, MediciNova can sell its common stock over 36 months at 97% of the market price to finance R&D and corporate activities. The company's President and CEO, Dr. Yuichi Iwaki, emphasized the flexibility and strategic benefits of this arrangement for advancing their programs and capitalizing on market conditio...
07-31 23:30
Immunovia’s PancreaSure Test Gains Prestigious Recognition
Immunovia AB ( ($SE:IMMNOV) ) has issued an announcement. Immunovia AB’s analyt...
07-28 15:32
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
07-24 20:35
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
MediciNova, Inc. reports that its Phase 2/3 COMBAT-ALS trial for MN-166 is nearing completion of patient randomization, with enrollment down to single digits. Concurrently, its Phase 2 trial for MN-001 in type 2 diabetes patients with dyslipidemia and fatty liver disease is seeking its final two participants. Dr. Yuichi Iwaki, the company's CEO, expressed optimism about these programs, highlighting their potential to address significant unmet med...
07-24 10:00
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome
Minovia Therapeutics Ltd. announced that the U.S. FDA has granted Fast Track and Rare Pediatric Disease Designations to its lead compound MNV-201 for Pearson Syndrome, a life-threatening mitochondrial disorder. These designations aim to accelerate development and review, potentially reducing time to market and offering financial benefits via a pediatric priority review voucher. MNV-201 is a first-in-class mitochondrial cell therapy currently in P...
06-30 12:30
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
美股大行评级 | 超配！Hinge Health获多家大行首予评级； Oppenheimer上调Mate目标价从665美元升至775美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持SurgePays Inc(SURG)"买入"评级，目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital：维持LiqTech Internatio
06-17 09:46
B. Riley Securities Maintains Buy on MediciNova, Lowers Price Target to $5
B. Riley Securities analyst Mayank Mamtani maintains MediciNova (NASDAQ:MNOV) with a Buy and lowers the price target from $6 to $5.
06-17 01:34
Immunovia Validates Pancreatic Cancer Detection Technology
Immunovia AB ( ($SE:IMMNOV) ) has issued an announcement. Immunovia has publish...
06-09 15:32
Immunovia’s PancreaSure Gains Recognition at EDRN Workshop
Immunovia AB ( ($SE:IMMNOV) ) just unveiled an update. Immunovia has been selec...
05-21 16:24
